HRS-8080 clinical trials
Also written HRS-8080.
How each study uses HRS-8080 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the HRS-8080 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2026 (5)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 0
Often tested with
Tested in the same studies.
Dalpiciclib isethionate (2) · HRS-6209 (1) · HRS-1358 (1) · Trastuzumab rezetecan (1) · Ruzaltatug rezetecan (1) · Adebrelimab (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test HRS-8080, phase 3 first.
- Aug 2027A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast CancerPhase 3 · Shandong Suncadia Medicine Co., Ltd.
- Feb 2027A Drug-Drug Interaction Study of Rifampicin and Oral HRS-8080Phase 1 · Shandong Suncadia Medicine Co., Ltd.
Studies
Open first, then newest update. How each study uses HRS-8080 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- A Drug-Drug Interaction Study of Rifampicin and Oral HRS-8080Not yet recruitingPhase 1Shandong Suncadia Medicine Co., Ltd.NCT07876596Written as HRS-8080
- A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast CancerRecruitingPhase 3Shandong Suncadia Medicine Co., Ltd.NCT07024173Written as HRS-8080 Tablet
- A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.RecruitingPhase 3Shandong Suncadia Medicine Co., Ltd.NCT07354022Written as HRS-8080 Tablet ; Dalpiciclib Isethionate
- A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast CancerRecruitingPhase 3Shandong Suncadia Medicine Co., Ltd.NCT07349069Written as HRS-8080 Tablets
- A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast CancerRecruitingPhase 1/2Shandong Suncadia Medicine Co., Ltd.NCT07389733Written as HRS-8080 Tablet
- A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer PatientsRecruitingPhase 1/2Shandong Suncadia Medicine Co., Ltd.NCT06679036Written as HRS-8080
- Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast CancerRecruitingPhase 1/2Shandong Suncadia Medicine Co., Ltd.NCT06167694Written as HRS-8080; Dalpiciclib Isethionate Tablets
- Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast CancerRecruitingPhase 1/2Shandong Suncadia Medicine Co., Ltd.NCT06222879Written as HRS-8080; SHR-A1811
- A Trial of HRS-8080 Tablets in Metastatic or Local Advanced Breast Cancer of AdultsEnrolling by invitationPhase 1Shandong Suncadia Medicine Co., Ltd.NCT05189717Written as HRS-8080 tablets、SHR 6390 tablets、Abemaciclib、Everolimus
- A Study to Assess the Mass Balance of [14C]HRS-8080 in Healthy Chinese Postmenopausal Female Subjects.CompletedPhase 1Shandong Suncadia Medicine Co., Ltd.NCT07320521Written as [14C]HRS-8080
- A Clinical Study to Evaluate the Relative Bioavailability and Food Effect of HRS-8080 in Healthy SubjectsCompletedPhase 1Shandong Suncadia Medicine Co., Ltd.NCT06619873Written as HRS-8080
- A Trial of Itraconazole Effect on HRS-8080 Pharmacokinetics in Healthy ParticipantsCompletedPhase 1Shandong Suncadia Medicine Co., Ltd.NCT07229560Written as HRS-8080 Tablet